STROMEDIX
Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.
STROMEDIX
Industry:
Biotechnology Health Care Medical Device
Founded:
2006-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.stromedix.com
Total Employee:
11+
Status:
Closed
Contact:
617.674.8400
Email Addresses:
[email protected]
Total Funding:
28 M USD
Technology used in webpage:
SPF Amazon Amazon Ohio Region NameBright
Similar Organizations
Artes Medical
Artes Medical is a medical technology company focused on developing, manufacturing.
Grace Therapeutics
Grace Therapeutics is a pharmaceutical company that focuses on drug delivery treatment for rare and orphan diseases.
Kintai Therapeutics
Kintai is a biotechnology company that advancing precision therapeutics based on enteric signaling networks in the human body.
Current Employees Featured
Founder
Investors List
Bessemer Venture Partners
Bessemer Venture Partners investment in Series B - Stromedix
Atlas Venture
Atlas Venture investment in Series B - Stromedix
Red Abbey Venture Partners
Red Abbey Venture Partners investment in Series B - Stromedix
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - Stromedix
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Stromedix
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Stromedix
Atlas Venture
Atlas Venture investment in Series A - Stromedix
Official Site Inspections
http://www.stromedix.com
- Host name: 104.21.50.90
- IP address: 104.21.50.90
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Stromedix"
Stromedix - Crunchbase Company Profile & Funding
Organization. Stromedix . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Storemedix is a biomedical company focused on …See details»
Stromedix 2025 Company Profile: Valuation, Investors ... - PitchBook
Stromedix was founded in 2006. Where is Stromedix headquartered? Stromedix is headquartered in Cambridge, MA. What industry is Stromedix in? Stromedix’s primary industry is …See details»
Stromedix, Inc. Company Profile | Cambridge, MA | Competitors ...
Find company research, competitor information, contact details & financial data for Stromedix, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Stromedix - Ownership and Business Overview - Mergr
Stromedix, Inc., is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrosis and organ failure. Stromedix's investors include …See details»
Stromedix - Products, Competitors, Financials, Employees, …
Stromedix is a biomedical company focused on drugs for fibrosis, organ failure and cancer. In 2012, Stromedix was acquired by Biogen Idec. Stubhub Stubhub Bessemer originally invested …See details»
Biogen Idec to Acquire Stromedix
Idec s research organization from 2000 to 2005. We appreciate Biogen Idec s focus in immunology and their tremendous international R&D and commercial capabilities. By joining …See details»
Stromedix - Company Profile - Tracxn
Oct 5, 2024 Stromedix - Develops drugs for fibrosis. Acquired by Biogen. Raised a total funding of $26M over 3 rounds from 5 investors. Stromedix has 263 competitors.See details»
Organization | Stromedix
Organization Overview. First Clinical Trial. 2010 NCT00878761. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Stromedix, Inc. Active Ingredients. Drugs in …See details»
Stromedix - VentureRadar
Stromedix is advancing therapeutics for treatment of end-organ fibrosis. ... Find out more about Stromedix, Healthtech and Life Sciences.See details»
Stromedix - Crustdata Company Profile, Funding and Growth
Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer. Company …See details»
Stromedix - Bessemer Venture Partners
Stromedix Stromedix is a biomedical company focused on drugs for fibrosis, organ failure and cancer. In 2012, Stromedix was acquired by Biogen Idec. ACQUIRED BY: BIOGEN IDEC. …See details»
Biogen acquires Stromedix to pursue novel fibrosis therapy
Mar 30, 2012 Biogen Idec has agreed to buy Stromedix for an upfront fee of US$75 million and up to $487.5 million in milestone payments. Stromedix is a privately held biotechnology …See details»
Stromedix - Contacts, Employees, Board Members, Advisors
Storemedix is a biomedical company focused on drugs for fibrosis, organ failure and cancer.See details»
Biogen Idec to Acquire Stromedix - Pharmaceutical Processing …
Feb 14, 2012 Stromedix’s lead candidate, STX-100, is a novel humanized monoclonal antibody that selectively disrupts the TGF-beta pathway, which plays a central role in fibrotic disease. ...See details»
Biogen Idec to Acquire Stromedix | Fierce Biotech
Feb 14, 2012 Biogen Idec to Acquire Stromedix -- Stromedix Brings Highly Differentiated Candidate for Treatment of Fibrosis and Core Scientific Team Focused on the Phase 2 …See details»
Biogen to acquire developer of fibrosis treatments | Reuters
Biogen Idec Inc <BIIB.O> has agreed to acquire Stromedix Inc, a privately held company developing treatments for fibrosis and organ failure, for $75 million cash and additional …See details»
Biogen Idec, Inc. (Massachusetts) to Pay Up to $562.5 ... - BioSpace
Feb 14, 2012 “With a well-established understanding of the fundamental biology and tremendous unmet medical need, fibrosis is one of the most exciting and dynamic areas of …See details»
Emerging Drug Developer: Stromedix | Fierce Biotech
Stromedix grooms itself for an M&A deal As the CEO of Cambridge, MA-based Stromedix, a developer headed into a mid-stage trial of its one and only therapy, Mike Gilman has a lot of …See details»
Biogen Idec to acquire Stromedix - European Pharmaceutical Review
Feb 14, 2012 “With a well-established understanding of the fundamental biology and tremendous unmet medical need, fibrosis is one of the most exciting and dynamic areas of …See details»
Biogen Buying Out Former Exec's Biotech Startup
Feb 14, 2012 Biogen and Stromedix have a family connection, so to speak, since Stromedix's founder and chief, Mike Gilman, was Biogen's R&D head from 2000 to 2005. In a post on …See details»